Geneseeq at AMP 2026

  • Start date: Nov 10, 2026
  • End date: Nov 14, 2026
  • Location: Seattle Convention Center
  • Booth: Booth 1919
Schedule a Meeting

Join Geneseeq in Seattle, USA | November 10-14, 2026

Join Geneseeq in Seattle at the AMP 2026 Annual Meeting & Expo to explore our latest work in comprehensive genomic profiling, tumor-naïve MRD, and AI-driven cfDNA fragmentomics.

With seven posters showcasing emerging biomarkers and innovative AI technologies, our research at AMP 2026 highlights advances in assay development, clinically relevant biomarkers, and molecular profiling.

Discover Geneseeq at AMP 2026

1. Comprehensive Genomic Profiling

Geneseeq offers comprehensive genomic profiling and assay validation capabilities for solid tumors, supporting reliable detection of clinically relevant genomic alterations in FFPE samples. The GENESEEQPRIME® NGS Tumor Profiling Assay is FDA 510(k)-cleared, reflecting our focus on standardized, validated genomic testing for precision oncology.

2. KRAS & MTAP Biomarker Validation Research

At AMP 2026, we will also highlight analytical validation research focused on KRAS alterations and MTAP deletion. KRAS plays a central role in precision oncology and targeted therapy development, while MTAP deletion is gaining increasing attention as new biomarker-driven therapeutic strategies move through clinical development. These studies show Geneseeq’s capabilities in supporting molecular pathology, clinical laboratory, and translational research teams working with clinically relevant oncology biomarkers.

3. Tumor-Naïve cfDNA MRD

Geneseeq continues to advance tumor-naïve cfDNA approaches for molecular residual disease detection and postoperative recurrence-risk stratification.

Our AMP 2026 research spans longitudinal, multimodal, and multi-omic cfDNA analysis in NSCLC and across solid tumors, exploring blood-based approaches to improve residual disease detection and refine postoperative risk assessment. Geneseeq offers SHIELDING ULTRA™, a fixed-panel MRD solution that integrates mutation, CNV, and fragmentomic features to support sensitive detection within a standardized workflow.

4. AI-Driven cfDNA Fragmentomics

Geneseeq is applying AI-driven cfDNA fragmentomics to improve the detection and interpretation of complex cfDNA signals.

At AMP 2026, our research features Fragmentia-AI™ and complementary approaches including somatic variant classification, fragment-level cfDNA analysis, and DNA language models, with applications in tumor-naïve MRD detection and recurrence-risk stratification.

Visit Booth 1919 to meet our team, learn more about our latest research, and discuss how Geneseeq can support your clinical, laboratory, and translational research needs.

Featured Research at AMP 2026

Friday, November 13

Poster Session · 9:15 a.m.
I013 Informatics

Analytical Validation of a Comprehensive Genomic Profiling NGS Kit for Clinically Relevant KRAS Alterations in FFPE Tumors

Abstract No. 2461668

ST064 Solid Tumors

Longitudinal Tumor-Naïve Multimodal cfDNA MRD Monitoring for Postoperative Recurrence-Risk Stratification in NSCLC

Abstract No. 2465287

ST136 Solid Tumors

Deep Learning–Based Somatic Variant Classification Enables Tumor-Naïve cfDNA MRD Detection and Recurrence Risk Stratification

Abstract No. 2464472

Saturday, November 14

Poster Session · 9:15 a.m.
I014 Informatics

Analytical Validation of MTAP Deletion Detection in a Comprehensive Genomic Profiling Assay for Solid Tumors

Abstract No. 2461688

I015 Informatics

Comprehensive Validation of a Tumor Profiling NGS Assay for FFPE Solid Tumors

Abstract No. 2461792

ST061 Solid Tumors

Ultrasensitive Tumor-Naïve Multi-Omic cfDNA Analysis for Molecular Residual Disease Detection Across Solid Tumors

Abstract No. 2464548

ST137 Solid Tumors

Mutation-Masked Fragment-Level cfDNA Inference for MRD-Based Risk Stratification Using a DNA Language Model

Abstract No. 2464583


Connect with Geneseeq at AMP 2026

Complete the form below to schedule a meeting in advance or stay connected with our team during the congress.